ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
28 announcements
Hikal Ltd held its 38th AGM on September 23, 2026, approving financial statements, director appointments, remuneration revisions, and declaring a total dividend of ₹0.60 per share.
Hikal has begun commercial production at its new cGMP Panoli facility, entering Personal Care manufacturing. First batches of UV filters and skincare ingredients are now being supplied to global customers.
Hikal Ltd has filed its Business Responsibility and Sustainability Report for FY 2025-26, fulfilling regulatory compliance requirements under SEBI (LODR) Regulations, 2015.
Hikal Limited has submitted its Annual Report for FY 2025-26 and the Notice of its 38th Annual General Meeting to the stock exchanges.
Hikal Ltd has scheduled its 38th Annual General Meeting for September 23, 2026. The company fixed September 04, 2026, as the record date for final dividend eligibility.
Hikal Limited has appointed Mr. Sameer Hiremath as Chairman and Managing Director for five years. The appointment is effective from October 1, 2026, subject to shareholder approval.
Hikal reported Q1 FY27 revenue of Rs 403 Cr with 9.2% EBITDA margin. Results show recovery post-regulatory disruption, driven by Pharma and Animal Health scaling.
Hikal Ltd. reported Q1 FY27 revenue of ₹403 Crore, with EBITDA of ₹37 Crore. The release details segment performance and operational updates for the quarter.
Hikal reported Q1FY27 revenue of ₹403 Cr, up 6% YoY. Focus remains on pharma remediation and commissioning the Panoli facility for Personal Care.
Hikal Ltd reported revenue from operations of ₹402.8 Cr (+5.9% YoY) and a net loss of ₹7.4 Cr for Q1 FY27.
Hikal Ltd. scheduled a board meeting for August 06, 2026, to consider and approve standalone and consolidated unaudited financial results for the June quarter.
Hikal Ltd. has been awarded the EcoVadis Gold Medal for its sustainability performance, placing the company in the top 5% of companies assessed by EcoVadis globally.
Hikal Ltd filed its quarterly shareholding pattern. The disclosure includes a conversion of Castilia Life Sciences Private Limited into an LLP.
Hikal Ltd's postal ballot for appointing an Independent Director passed with 99.99% approval. The Scrutinizer's report confirms the resolution's validity and compliance.
Hikal Ltd has issued a Postal Ballot notice to seek shareholder approval for appointing Mr. Sandip Parikh as an Independent Director. Voting runs from June to July.
Q4FY26 revenue hit ₹519cr with 20.3% EBITDA margin. Management focuses on transition from remediation to sustainable technology-led growth despite US FDA and raw material headwinds.
Hikal Limited recommended a final dividend of 0.2 per equity share for FY 2025-26. The record date will be determined during the upcoming Annual General Meeting.
Hikal Limited appointed Mr. Sandip Parikh as Independent Director and Mr. Ravi Khadabadi to Senior Management. These appointments strengthen the company's governance and operational leadership.
Hikal is navigating a difficult recovery phase, masked by a massive ₹47cr impairment and USFDA warning letter at Bangalore. While margins show sequential improvement, the core business remains stagnant and heavily reliant on regulatory resolution.
Hikal Limited reported Q4 Revenue of ₹519 Crore and EBITDA of ₹105 Crore. The board approved a final dividend of 20% for FY26.
Hikal reported Q4 FY26 revenue of Rs 519 Cr with a 20.3% EBITDA margin. Full year FY26 revenue reached Rs 1,713 Cr, though exceptional items led to a consolidated net loss of Rs 49 Cr.
Hikal Limited reported that external reviews of employee irregularities revealed revenue preponement issues. Involved employees were terminated, and management confirmed no financial impact on current periods.
Hikal Ltd reported revenue from operations of ₹519.4 Cr (-6.0% YoY) and net profit of ₹14.4 Cr (-71.3% YoY) for Q4 FY26.
Hikal Limited reported its FY2025-26 audited financial results and recommended a 20% final dividend. The board also approved appointing Sandip Parikh as an Independent Director.
Hikal Ltd scheduled a Board Meeting on May 27, 2026, to approve audited FY26 financial results. The board will also consider recommending a final dividend.
Hikal Ltd announced that Mr. Vimaldeep Kulshrestha, President- Crop Protection, will superannuate on April 14, 2026. He will cease to be an employee of the company from the end of business hours on that date. This transition marks the departure of a senior management personnel.
Hikal Limited clarified an inadvertent error in its XBRL filing for the quarter ended September 30, 2025. EPS figures were mistakenly reported under discontinued operations instead of continuing operations. The company confirmed that the PDF filing was correct, showing quarterly EPS of Rs. (2.81) and year-to-date EPS of Rs. (4.65).
Hikal Ltd submitted its quarterly certificate under Regulation 74(5) of SEBI (Depositories and Participants) Regulations for the period ended March 31, 2026. The Registrar and Share Transfer Agent, MUFG Intime India, confirmed that security certificates received for dematerialisation were processed and listed on the exchanges within prescribed timelines.